A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b

Takashi Imada, Koji Moriya, Masahiko Uchiyama, Naoto Inukai, Mitsuhiro Hitotsuyanagi, Akiko Masuda, Takehiro Suzuki, Shotaro Ayukawa, Yo Ichi Tagawa, Naoshi Dohmae, Michinori Kohara, Masayuki Yamamura, Daisuke Kiga

    Research output: Contribution to journalArticle

    Abstract

    Although conjugation with polyethylene glycol (PEGylation) improves the pharmacokinetics of therapeutic proteins, it drastically decreases their bioactivity. Site-specific PEGylation counters the reduction in bioactivity, but developing PEGylated proteins with equivalent bioactivity to that of their unmodified counterparts remains challenging. This study aimed to generate PEGylated proteins with equivalent bioactivity to that of unmodified counterparts. Using interferon (IFN) as a model protein, a highly bioactive Lys-deficient protein variant generated using our unique directed evolution methods enables the design of a site-specific di-PEGylated protein. Antiviral activity of our di-PEGylated IFN was similar to that of unmodified IFN-α2b. The di-PEGylated IFN exhibited 3.0-fold greater antiviral activity than that of a commercial PEGylated IFN. Moreover, our di-PEGylated IFN showed higher in vitro and in vivo stability than those of unmodified IFN-α2b. Hence, we propose that highly bioactive Lys-deficient proteins solve the limitation of conventional PEGylation with respect to the reduction in bioactivity of PEGylated proteins.

    Original languageEnglish
    JournalACS Synthetic Biology
    DOIs
    Publication statusAccepted/In press - 2018 Jan 1

    Fingerprint

    Interferons
    Bioactivity
    Proteins
    Antiviral Agents
    Pharmacokinetics
    Polyethylene glycols

    Keywords

    • directed evolution
    • genetic code engineering
    • interferon
    • Lys-deficient proteins
    • site-specific di-PEGylation

    ASJC Scopus subject areas

    • Biomedical Engineering
    • Biochemistry, Genetics and Molecular Biology (miscellaneous)

    Cite this

    A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b. / Imada, Takashi; Moriya, Koji; Uchiyama, Masahiko; Inukai, Naoto; Hitotsuyanagi, Mitsuhiro; Masuda, Akiko; Suzuki, Takehiro; Ayukawa, Shotaro; Tagawa, Yo Ichi; Dohmae, Naoshi; Kohara, Michinori; Yamamura, Masayuki; Kiga, Daisuke.

    In: ACS Synthetic Biology, 01.01.2018.

    Research output: Contribution to journalArticle

    Imada, T, Moriya, K, Uchiyama, M, Inukai, N, Hitotsuyanagi, M, Masuda, A, Suzuki, T, Ayukawa, S, Tagawa, YI, Dohmae, N, Kohara, M, Yamamura, M & Kiga, D 2018, 'A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b', ACS Synthetic Biology. https://doi.org/10.1021/acssynbio.8b00188
    Imada, Takashi ; Moriya, Koji ; Uchiyama, Masahiko ; Inukai, Naoto ; Hitotsuyanagi, Mitsuhiro ; Masuda, Akiko ; Suzuki, Takehiro ; Ayukawa, Shotaro ; Tagawa, Yo Ichi ; Dohmae, Naoshi ; Kohara, Michinori ; Yamamura, Masayuki ; Kiga, Daisuke. / A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b. In: ACS Synthetic Biology. 2018.
    @article{73d914e56a8c4fcba979ed4427d6f261,
    title = "A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b",
    abstract = "Although conjugation with polyethylene glycol (PEGylation) improves the pharmacokinetics of therapeutic proteins, it drastically decreases their bioactivity. Site-specific PEGylation counters the reduction in bioactivity, but developing PEGylated proteins with equivalent bioactivity to that of their unmodified counterparts remains challenging. This study aimed to generate PEGylated proteins with equivalent bioactivity to that of unmodified counterparts. Using interferon (IFN) as a model protein, a highly bioactive Lys-deficient protein variant generated using our unique directed evolution methods enables the design of a site-specific di-PEGylated protein. Antiviral activity of our di-PEGylated IFN was similar to that of unmodified IFN-α2b. The di-PEGylated IFN exhibited 3.0-fold greater antiviral activity than that of a commercial PEGylated IFN. Moreover, our di-PEGylated IFN showed higher in vitro and in vivo stability than those of unmodified IFN-α2b. Hence, we propose that highly bioactive Lys-deficient proteins solve the limitation of conventional PEGylation with respect to the reduction in bioactivity of PEGylated proteins.",
    keywords = "directed evolution, genetic code engineering, interferon, Lys-deficient proteins, site-specific di-PEGylation",
    author = "Takashi Imada and Koji Moriya and Masahiko Uchiyama and Naoto Inukai and Mitsuhiro Hitotsuyanagi and Akiko Masuda and Takehiro Suzuki and Shotaro Ayukawa and Tagawa, {Yo Ichi} and Naoshi Dohmae and Michinori Kohara and Masayuki Yamamura and Daisuke Kiga",
    year = "2018",
    month = "1",
    day = "1",
    doi = "10.1021/acssynbio.8b00188",
    language = "English",
    journal = "ACS Synthetic Biology",
    issn = "2161-5063",
    publisher = "American Chemical Society",

    }

    TY - JOUR

    T1 - A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b

    AU - Imada, Takashi

    AU - Moriya, Koji

    AU - Uchiyama, Masahiko

    AU - Inukai, Naoto

    AU - Hitotsuyanagi, Mitsuhiro

    AU - Masuda, Akiko

    AU - Suzuki, Takehiro

    AU - Ayukawa, Shotaro

    AU - Tagawa, Yo Ichi

    AU - Dohmae, Naoshi

    AU - Kohara, Michinori

    AU - Yamamura, Masayuki

    AU - Kiga, Daisuke

    PY - 2018/1/1

    Y1 - 2018/1/1

    N2 - Although conjugation with polyethylene glycol (PEGylation) improves the pharmacokinetics of therapeutic proteins, it drastically decreases their bioactivity. Site-specific PEGylation counters the reduction in bioactivity, but developing PEGylated proteins with equivalent bioactivity to that of their unmodified counterparts remains challenging. This study aimed to generate PEGylated proteins with equivalent bioactivity to that of unmodified counterparts. Using interferon (IFN) as a model protein, a highly bioactive Lys-deficient protein variant generated using our unique directed evolution methods enables the design of a site-specific di-PEGylated protein. Antiviral activity of our di-PEGylated IFN was similar to that of unmodified IFN-α2b. The di-PEGylated IFN exhibited 3.0-fold greater antiviral activity than that of a commercial PEGylated IFN. Moreover, our di-PEGylated IFN showed higher in vitro and in vivo stability than those of unmodified IFN-α2b. Hence, we propose that highly bioactive Lys-deficient proteins solve the limitation of conventional PEGylation with respect to the reduction in bioactivity of PEGylated proteins.

    AB - Although conjugation with polyethylene glycol (PEGylation) improves the pharmacokinetics of therapeutic proteins, it drastically decreases their bioactivity. Site-specific PEGylation counters the reduction in bioactivity, but developing PEGylated proteins with equivalent bioactivity to that of their unmodified counterparts remains challenging. This study aimed to generate PEGylated proteins with equivalent bioactivity to that of unmodified counterparts. Using interferon (IFN) as a model protein, a highly bioactive Lys-deficient protein variant generated using our unique directed evolution methods enables the design of a site-specific di-PEGylated protein. Antiviral activity of our di-PEGylated IFN was similar to that of unmodified IFN-α2b. The di-PEGylated IFN exhibited 3.0-fold greater antiviral activity than that of a commercial PEGylated IFN. Moreover, our di-PEGylated IFN showed higher in vitro and in vivo stability than those of unmodified IFN-α2b. Hence, we propose that highly bioactive Lys-deficient proteins solve the limitation of conventional PEGylation with respect to the reduction in bioactivity of PEGylated proteins.

    KW - directed evolution

    KW - genetic code engineering

    KW - interferon

    KW - Lys-deficient proteins

    KW - site-specific di-PEGylation

    UR - http://www.scopus.com/inward/record.url?scp=85056135406&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85056135406&partnerID=8YFLogxK

    U2 - 10.1021/acssynbio.8b00188

    DO - 10.1021/acssynbio.8b00188

    M3 - Article

    C2 - 30277749

    AN - SCOPUS:85056135406

    JO - ACS Synthetic Biology

    JF - ACS Synthetic Biology

    SN - 2161-5063

    ER -